Cyclacel Pharmaceuticals has entered into a definitive agreement to sell four of its patents related to the use of the romidepsin injection to Celgene Corporation.
Baker & McKenzie has hired Christian Alejandro López-Silva as head of its pharmaceutical and life sciences group in Mexico.
Generic drug-maker Actavis believes it will earn profits of around $100 million in the next two years from licensing patents owned by Purdue Pharma LP.
Indian pharmaceutical company Orchid Chemicals and Pharmaceuticals has entered into a partnership with new European biopharmaceutical company Allecra Therapeutics.
The US Federal Trade Commission has published its annual report for 2012, in which it remains critical of “pay-for-delay” patent settlements.
Japanese pharma Shionogi has brought a lawsuit against Hospira Inc to keep it from marketing a generic version of Shionogi’s Doribax, alleging it infringes one of the company’s patents.
The UK Office of Fair Trading has accused GlaxoSmithKline of abusing its market dominance and infringing UK competition law by paying rivals to delay releasing generic versions of its anti-depressant Seroxat.
Swiss pharmaceutical firm Novartis has filed a lawsuit against Accord Healthcare, Fresenius Kabi and Hikma Farmaceutica for applying to market generic versions of its cancer drug Zometa.
The US Supreme Court has heard oral arguments on whether genetic material is patent eligible subject matter. Jennifer Camacho, shareholder at Greenberg Traurig, reports on Monday's proceedings.
Myriad Genetics will deliver an oral argument at the US Supreme Court today defending its patents covering isolated human gene sequences linked to breast and ovarian cancer.